Good Morning farm country. Davis Michaelsen here with your morning update for Wednesday, March3. From Pro Farmers First Thing Today, these are some of the stories we are watching this morning:
Corn futures faced pressure through the overnight session and the market is down 1 to 5cents, with old-crop contracts leading the decline. Soybean futures are a penny higher in the front-month but 2 to 5 cents lower in deferred contracts. SRW wheat futures are down 5 to 6 cents, while HRW and HRS wheat futures are posting losses more in the 1 to 3cent area. Crude oil futures are pushing to the upside, while the U.S. dollar index is posting modest gains.
Chinese soybean futures on the Dalian Commodity Exchange shot more than 3% higher to another record-high on Wednesday, the second record-breaking move this week. Rising prices for edible oil and expectations for delayed arrivals of Brazilian soybeans have lifted the market.
The Senate today will begin its long floor process on the latest coronavirus/stimulus aid bill. The chamber will have another late-night vote-a-rama, potentially on Thursday, on amendments to the bill. Senate Democrats hope to pass the bill by the end of the week.
President Joe Biden on Tuesday said that the U.S. will now have enough Covid-19 vaccines for every adult by the end of May and that the government will start a new program aimed at vaccinating all teachers by the end of March.
Senate Finance Committee members are frustrated with the administration of Mexican President Andrs Manuel Lpez Obrador as seen in a set of written questions for USTR nominee Katherine Tai. At least nine members of the committee raised concerns about recent Mexican government actions that threaten U.S. farm exports and energy trade.
House Democrats have unveiled an expansive climate bill. The measure would zero out domestic greenhouse gas emissions by 2050. The 981-page draft bill would set a U.S. goal to reduce greenhouse emissions by at least 50%, from 2005 levels, by 2030 it calls for a federal clean energy standard that sets an interim goal of 80% clean electricity by 2030 and 100% by 2035.
African swine fever (ASF) has been detected in piglets being illegally transported through Chinas Yunnan province, the countrys ag ministry reported. Six of the 36 piglets involved had died and another six were sick. This comes at a time when concern about another wave of the virus is rising.
Boxed beef values dropped on Tuesday, narrowing the spread between the grades. Movement picked up a bit to 112 loads. The sharp price retreat adds to ideas the product market has likely topped.
Nearby lean hog contracts sustained heavy losses Tuesday, a signal that a deeper correction may lie ahead, with the front-month violating uptrending support drawn off the lows since mid-January. But strength in the product and cash market could also help to stem the selling.
President Joe Bidens proposed $1.9 trillion coronavirus relief bill would phase out $1,400 payments to high-income Americans in a compromise with moderate Democratic senators, according to lawmakers and media reports.
The Democratic-controlled Senate expects to open debate on the package as early as Wednesday, with a final vote for passage seen later in the week. Before the bill hits the chamber floor, Democrats are negotiating limits to a measure Republicans have attacked as wasteful.
Senate Democrats said the proposal, which would block Americans earning $80,000 per year or more and couples earning $160,000 or more from receiving the $1,400 payments, was a good solution.
The income cutoff had been higher $100,000 for individuals and $200,000 for couples filing jointly in the House-passed version of the legislation.
Its an appropriate way of bringing this to a successful conclusion, Sen. Michael Bennet told reporters. Sen. Debbie Stabenow said the caps would be a reasonable compromise.
The 100-seat chamber, where control is split 50-50 between Democrats and Republicans, will consider on Wednesday a motion to begin 20 hours of debate on the sweeping legislation. That vote could be an early indicator of how much Republican opposition the package faces.
The bill would pay for vaccines and medical supplies, boost jobless assistance and send a new round of emergency financial aid to households, small businesses and state and local governments. Democrats aim to get it to Biden to sign into law before March 14, when some current benefits expire.
The plan that we are going to vote on this week is going to provide real, robust relief for all of us, Senate Majority Leader Chuck Schumer said.
Republicans, led by Senate Minority Leader Mitch McConnell, have denounced the bill. On Wednesday McConnell called it a vast catalog of liberal spending and a partisan smorgasbord of borrowed money packed with crazy provisions unrelated to the pandemic, which has killed more than 517,000 Americans and left millions more jobless.
But a new Morning Consult/Politico poll showed strong bipartisan support for the measure is holding against the Republican attacks. It said 77% of all voters and 59% of Republicans backed the plan.
Before the legislation comes to a final vote, Democrats will have to sort out a bunch of competing ideas as they seek to advance the bill.
First to go will be a minimum-wage increase, which the Senate parliamentarian said last week could not be included in the package while the Democrats are using a special procedure that allows them to pass the bill with a simple majority, rather than the 60 votes needed to advance most legislation in the chamber.
With Democrats and their allies controlling 50 seats, Vice President Kamala Harris might need to give them a tie-breaking vote.
, but so long as the Democrats remain united, they would not need Republican votes.
Democrats have shown no interest in dropping another partisan sticking point: $350 billion in aid for state and local governments, which face rising costs and uncertain tax revenues because of the pandemic. But they are negotiating what to include in that figure, with some advocating for spending on rural broadband internet service, a priority for senators from states with large rural populations.
A Reuters analysis found that Democratic-leaning states would get a larger share of that money this time around than they did under the first $150 billion of state and local aid that Congress approved last year.
Democratic Senator Joe Manchin, a key centrist, pushed to scale back enhanced unemployment benefits to $300 per week from $400.
Once the Senate votes on the bill, the House would then have to sign off on the changes before Biden can sign it into law. (Reporting by Susan Cornwell and Andy Sullivan; Additional reporting by David Morgan and Richard Cowan; Editing by Scott Malone, Peter Cooney, Steve Orlofsky and Jonathan Oatis)
Another two Mainers have died as health officials on Wednesday reported 147 more coronavirus cases across the state.
The number of coronavirus cases diagnosed in the past 14 days statewide is 2,219. This is an estimation of the current number of active cases in the state, as the Maine CDC is no longer tracking recoveries for all patients. Thats up from 2,176 on Tuesday.
In recent days, Maine has seen new coronavirus cases stabilize in the low triple digits. That comes after Maine saw an accelerating decline in confirmed virus transmission from mid-January when cases reached a record-high 830 through mid-February when they slipped below 100 for the first time in months.
Since then, Maine has seen active cases tick up, the seven-day average climb and a rise in its positivity rate.
Were not sure at this time what that increase may represent, Maine CDC Director Nirav Shah said during a Tuesday press conference. He said that his agencys epidemiologists are looking for patterns that may explain the trends Maine is seeing.
Shah said Maine has seen a remarkable decline in cases, but that decline has slowed.
While were not seeing those multiple of hundreds of cases that we saw six, seven, or eight weeks ago, were not seeing a continuation of that reduction, he said.
Two men in their 50s and 70s from York County have succumbed to the virus, bringing the statewide death toll to 705.
Wednesdays report brings the total number of coronavirus cases in Maine to 45,091, according to the Maine CDC. Thats up from 44,944 on Tuesday.
Of those, 35,411 have been confirmed positive, while 9,680 were classified as probable cases, the Maine CDC reported.
The new case rate statewide Wednesday was 1.10 cases per 10,000 residents, and the total case rate statewide was 336.90.
Maines seven-day average for new coronavirus cases is 171.6, down from 173.6 a day ago, up from 148.6 a week ago and down from 294.4 a month ago. That average peaked on Jan. 14 at 625.3.
The most cases have been detected in Mainers in their 20s, while Mainers over 80 years old make up the majority of deaths. More cases and deaths have been recorded in women than men. For a complete breakdown of the age and sex demographics of cases, hospitalizations and deaths, use the interactive graphic below.
So far, 1,545 Mainers have been hospitalized at some point with COVID-19, the illness caused by the new coronavirus. Of those, 67 are currently hospitalized, with 24 in critical care and eight on a ventilator. Currently, 110 out of 399 critical care beds and 255 out of 319 ventilators are available. Meanwhile, 446 alternative ventilators are available.
The total statewide hospitalization rate on Wednesday was 11.54 patients per 10,000 residents.
Cases have been reported in Androscoggin (4,849), Aroostook (1,288), Cumberland (12,647), Franklin (909), Hancock (918), Kennebec (3,674), Knox (658), Lincoln (585), Oxford (2,239), Penobscot (3,963), Piscataquis (303), Sagadahoc (890), Somerset (1,251), Waldo (595), Washington (725) and York (9,593) counties. Information about where an additional four cases were reported wasnt immediately available.
For a complete breakdown of the county by county data, use the interactive graphic below.
Overall, 1,886,417 COVID-19 tests have been administered and the statewide positivity rate is 2.84 percent.
An additional 5,431 Mainers have been vaccinated against the coronavirus in the previous 24 hours. As of Wednesday, 236,784 Mainers have received a first dose of the vaccine, while 127,647 have received two doses.
As of Wednesday evening, the coronavirus had sickened 28,771,556 people in all 50 states, the District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands and the U.S. Virgin Islands, as well as caused 518,900 deaths, according to the Johns Hopkins University of Medicine.
Nationwide, 80.5 million doses of the vaccine have been administered, an increase of 1.9 million doses since Tuesday, according to Bloomberg.
Correction: A previous version of this story misstated the number of second doses of the COVID-19 vaccine administered in Maine.
News that the governor of Texas, Republican Greg Abbott, would lift the states face-mask mandate and allow businesses to fully reopen on March 10 was met with a wave of alarm on Wednesday, as health officials warned that the U.S. is not out of the woods, even as the vaccine program looked set to get a needed boost.
Abbott announced the news in a tweet that was immediately greeted with dismay.
Gilberto Hinojosa, chairman of the Texas Democratic Party, said the move was extraordinarily dangerous and will kill Texans.
This will set us back, not move us forward.
Our countrys infectious-disease specialists have warned that we should not put our guard down even as we make progress towards vaccinations. Abbott doesnt care, Hinojosa said in a statement.
[O]pening Texas prematurely will only lead to faster COVID spread, more sickness and overcrowding in our hospitals, and unnecessary deaths. There is no economic recovery without beating the coronavirus pandemic. This will set us back, not move us forward, said the statement.
Texas has the third highest number of deaths after California and New York at 44,353, according to a New York Times Tracker. The Lone Star State has had 2.7 million confirmed cases of COVID since the start of the pandemic, the tracker shows. Just 13% of the states population has received at least one vaccine jab so far, according to the Centers for Disease Control and Prevention, and just 6.8% of the states population has received two doses.
Dr. Irwin Redlener, a pediatrician who is head of theColumbia University National Center for Disaster Preparedness, said he was mortified and disgusted by the Texas move, which he called completely reckless.
If we dont have consistent policies around mass business openings, school openings, that means that theres going to be hideaways for the virus to start replicating even quicker, and that will spread to other communities that are being more responsible, Redlener told Sirius XM Doctor Radio Reports. So its not only reckless for the citizens of Texas; its reckless for all of us. So that will retard our ability to get this pandemic under control in America.
Dr. Lauren Ancel Meyers, a professor of integrative biology and director of the University of Texas COVID-19 Modeling Consortium, agreed. The fact that things are headed in the right direction doesnt mean we have succeeded in eradicating the risk, she said, as the Associated Press reported.
She said the recentdeadly winter freeze in Texasthat left millions of people without power forcing families to shelter closely with others who still had heat could have amplified transmission of the virus, although it remains too early to tell. Masks, she said, are one of the most effective strategies to curb the spread.
Companies responded to Abbotts move by saying they would continue to require customers and employees to wear face masks. Retailers Target Corp. TGT, +0.07% and Macys Inc. M, +4.14% said they would continue to do so, according to Reuters, while General Motors GM, -2.66% and Toyota TM, -0.25% 7203, -0.61% said they would stick with a face mask mandate for workers, the New York Times reported.
Kroger Co. also responded by saying it will continue to require its shoppers in Texas to wear face masks, as MarketWatchs Tonya Garcia reported.
To ensure the continued safety of our customers and associates, the Kroger Family of Companies will continue to require everyone in our stores across the country to wear masks until all our frontline grocery associates can receive the COVID-19 vaccine, the grocer said in a statement.
See: As governor reopens Texas, HPE says it will remain cautious
Local businesses got in on the act, too.
The news came as the head of the CDC continues to warn that a recent decline in U.S. case numbers has stalled at a level close to 70,000 new cases a day and about 2,000 deaths, as new variants that are far more infectious than the original virus circulate.
Just because were not getting 4,200 fatalities in a day were quote-unquote only getting 2,000 fatalities a day thats still horrible, really horrible, said Redlener. So we should not minimize where we are or somehow say, now were at a place where we can get back to normal. We cannot.
The U.S. continues to lead the world by case numbers and fatalities. With just 4% of the global population, the U.S. accounts for 28.7 million of the global case tally of 114.8 million, or about 25%. It has suffered 517,833 fatalities, or about 20% of the global toll of 2.55 million.
The news overshadowed President Joe Bidens announcement Tuesday that the White House is expecting to take delivery of enough coronavirus vaccine for all adults by the end of May two months earlier than anticipated.
Biden said supply would be greatly boosted by the news that Merck MRK, +0.62% will help produce rival Johnson & Johnsons JNJ, -1.76% newly authorized one-shot vaccine, likening the partnership between the two drug companies to the spirit of national cooperation during World War II.
For more, see: U.S. Covid vaccine supply to be boosted by Merck helping make J&J vaccine
Biden also cautioned against a rush to return to life as it was before the virus hit, echoing the concerns of his governments health experts.
The U.S. government stopped a clinical trial evaluating convalescent plasma as a treatment for people with mild to moderate forms of COVID-19, saying the experimental treatment likely has no benefit to these patients, MarketWatchs Jaimy Lee reported. Convalescent plasma is blood plasma gathered from people who have recovered from COVID-19; that plasma, which carries COVID-19 antibodies, is then given to people who are currently sick to help them recover from the disease. In this particular trial, the plasma was given to patients with at least one comorbidity who came to emergency rooms with mild or moderate symptoms of COVID-19. The NIH said that more than 100,000 people in the U.S. have been treated with convalescent plasma during the pandemic.
Country music legend Dolly Parton received her first shot of Modernas COVID-19 vaccine on Tuesday, quipping she got a dose of her own medicine, MarketWatchs Mike Murphy reported. Partondonated $1 million to COVID-19 researchat Vanderbilt University Medical Center in Nashville, Tenn., last year, which in turn helped the development of Modernas coronavirus vaccine. Im so excited. Ive been waiting a while, Parton, 75, said in a video posted Tuesday on social media. Im old enough to get it, and Im smart enough to get it.
A COVID testing center in the Netherlands was hit by an attempted bombing attack early Wednesday, according to Dutch media reports. The blast at a center in the town of Bovenkarspel, about 40 miles north of Amsterdam, blew out windows. The Netherlands has been hit with a wave of protests against a nationwide curfew that was imposed in January amid a wave of new cases.
New York will allow weddings of up to 150 people starting March 15, but with safety rules that include socially distanced dance zones, the Guardian reported. The move comes even as health experts fret about a new variant of the virus that has been uncovered in New York City that is more infectious than the original virus. All attendees must show proof of a negative PCR test within 72 hours of a wedding, or show proof of a negative rapid test within six hours of the event.
Slovakia has become the latest country to impose a curfew in an effort to contain one of the worlds highest mortality rates, AFP reported. Slovaks will be asked to stay home from 8 p.m. to 5 a.m., according to a government decree. The country of 5.4 million has the worlds highest rate of COVID deaths at 24 per 100,000 people, according to an AFP tally. In the neighboring Czech Republic, enforcement is being stepped up to restrict movement by people among the countrys districts.
Japan is considering a two-week extension of a state of emergency in the Tokyo area due to continuing pressure on the medical system from COVID-19 cases, Reuters reported. Prime Minister Yoshihide Suga will hold an advisory board meeting on Friday to decide on extending the emergency beyond the March 7 deadline. Suga said a shortage of beds in the capital region and a slow decline in infections prompted him to consider the move.
Read now: Money pressures from COVID-19 may finally push hospitals to stop wasting billions of dollars
Almost 65 million people have recovered from COVID-19, the Johns Hopkins data shows.
Brazil has the second highest death toll at 257,361 and is third by cases at 10.6 million.
India is second worldwide in cases with 11.1 million, and fourth in deaths at 157,346.
Mexico has the third highest death toll at 187,187 and 13th highest case tally at 2.1 million.
The U.K. has 4.2 million cases and 123,530 deaths, the highest in Europe and fifth highest in the world.
China,where the virus was first discovered late last year,has had 101,027 confirmed cases and 4,836 deaths, according to its official numbers.
The U.S. private sector added jobs in February at a slower pace than in the prior month, according to theADP National Employment Report released Wednesday.
Private-sector payrolls expanded by 117,000 jobs in February after adding a revised 195,000 in the prior month, MarketWatchs Greg Robb reported. This was a larger job gain in January than the initial estimate of an increase of 174,000.
Economists polled by the Wall Street Journal forecast a gain of 225,000 private sector jobs in February. The ADP report is produced with Moodys Analytics.
Overall, this report left cause for concern as the recovery remains tepid in the labor market, said T.J. Connelly, head of research at Contingent Macro.
Separately, the huge services side of the U.S. economy grew more slowly in February as businesses ran into shortages or delays in obtaining key materials, MarketWatchs Jeffry Bartash reported.
A survey of top business leaders at companies such as banks, hospitals and home builders slipped to a nine-month low of 55.3% last month from a two-year high of 58.7% in January, the Institute for Supply Management said Wednesday.
Readings above 50% signals that businesses are expanding, and numbers above 55% are usually a sign of broad strength.
The Federal Reserve will release its Beige Book report on economic conditions at 2 p.m. Eastern time.
The Dow Jones Industrial Average DJIA, -0.39% was up early Wednesday, while the S&P 500 SPX, -1.31% was down 0.5%.
BISMARCK North Dakota surpassed a total of 100,000 positive COVID-19 tests Wednesday, March 3, according to figures released by the state Department of Health.
That means that more than 13% of the state has registered a confirmed case of the virus since the pandemic began.
But even as Wednesday represented a benchmark, public health experts have long projected that there have been many more undocumented cases of COVID-19 in the state. One study by Columbia University researchers released in January even suggested that North Dakota's fall surge pushed infections to more than 60% of the population, a figure that would put the state close to herd immunity.
Public health officials have also celebrated a remarkable turnaround in North Dakota's virus outbreak in the last few months. Case numbers entered a sharp decline after a peak in mid-November. With case numbers now hovering in the high 500s and low 600s, North Dakota's virus levels are at their lowest point since last July.
And though the drivers of North Dakota's sharp reversal last fall have been debated in both political and public health circles, Dr. Paul Carson, a infectious disease specialist at North Dakota State University, noted in December that spread of the virus through much of the state's more risk-inclined population may mean that there have been many fewer people left for it to infect.
Following are the North Dakota Department of Health COVID-19 case rates, deaths, hospitalizations and vaccinations as of Wednesday. Because all data is preliminary, some numbers and totals may change from one day to the next.
North Dakota's active case count increased by 29 on Wednesday. Cass County reported 16 positive cases, while Burleigh County reported 12 additional cases.
ACTIVE HOSPITALIZATIONS: 20
DEATHS, NEWLY REPORTED: 1
TOTAL DEATHS: 1,448
The Department of Health reported the death of one Ward County man in his 70s.
FIRST DOSE ADMINISTERED: 137,039 (18.7% of the population)
COMPLETED SERIES (2 DOSES): 77,797 (10.6% of the population)
North Dakota continues to rank among the top states in the country in the vaccine rollout. A total of 232,079 shots have been administered to North Dakotans, and 91% of the doses received by the state have been administered. The Department of Health urges residents to seek more information at www.health.nd.gov/covidvaccinelocator.
As a public service, weve opened this article to everyone regardless of subscription status. If this coverage is important to you, please consider supporting local journalism by clicking on the subscribe button in the upper righthand corner of the homepage.
Readers can reach reporter Adam Willis, a Report for America corps member, at awillis@forumcomm.com.
More than 1.63 crore people have received a coronavirus vaccine in India so far. While there has been no case of any adverse effect on anyone, some recipients have reported some side-effects or mild illness.
A large number of experts have underlined that these are expected in a small number of cases and that these ought not to dissuade people from taking the shot.
Newsletter | Click to get the days best explainers in your inbox
Dr Shashank Joshi, member of Maharashtras Covid-19 task force, said both the vaccines being used in India, Bharat Biotechs Covaxin and Serum Institute of Indias Covishield, a version of the Oxford-AstraZeneca vaccine, are absolutely safe and minor side-effects are expected in some cases, not just for these particular vaccines, but any other vaccine as well.
Here are some of the things you need to know, and some precautions that you should take before getting vaccinated.
In case a person has allergies to medication, or drugs, it is important to get an all-clear from a medical practitioner. A complete blood count (CBC), C-reactive protein (CRP), or Immunoglobulin-E (IgE) levels can be checked under medical advice.
One should eat well and take medicines, if prescribed, ahead of vaccination. One should try to be as relaxed as possible; counselling can help people who are feeling anxious.
People with diabetes or blood pressure need to keep these in check. Cancer patients, especially those on chemotherapy, must act on medical advice.
People who have received blood plasma or monoclonal antibodies as part of Covid-19 treatment, or those who have been infected in the last one and a half months are advised to not take the vaccine right now.
A recipient of the vaccine is monitored at the vaccine centre itself to guard against any immediate severe allergic reaction. People are allowed to leave only after it has been ascertained that this is not the case.
Side effects like pain at the injection site and fever are common. This is no reason to panic. Some other side effects like chills and fatigue might also be expected, but these go away in a few days.
Vaccines teach our immune system how to recognise and fight an external threat in this case, the virus that causes Covid-19. It typically takes a few weeks after vaccination for the body to build protection (immunity) against the virus.
This means that a person could still get infected by Covid-19 in the few days immediately following the vaccination, because the person would not have had enough time to develop immunity.
Therefore, basic precautionary measures must be followed even after vaccination. Face masks, hand hygiene, and physical distancing in public places must not be abandoned just because a vaccine has been taken. Cough/sneeze etiquette also needs to be followed.
CLEVELAND, Ohio Readers have questions related to the second COVID-19 vaccine shot, especially if people who have recovered should get the second shot, and about allergic reactions and side effects.
Were providing answers from health care experts.
If you have specific questions concerning how a pre-existing condition or pregnancy may affect your ability to take the COVID-19 vaccine, please ask your primary care physician. Find out if you can ask questions via email, or arrange for a telehealth visit to get your concerns taken care of.
Q: Should individuals who have recovered from COVID-19 get the vaccine? Do they need both shots?
A: Health experts say its beneficial and safe for people who had COVID-19 to also get the vaccine.
The protection that comes from recovering from COVID-19 is called natural immunity, according to the Centers for Disease Control and Prevention. It happens because the body has created antibodies against the coronavirus, and those antibodies help protect against subsequent infections.
A vast majority of people infected with COVID-19 produce at least some antibodies. The vaccine will boost the natural immune response already in place from having recovered from the illness, health experts say.
The immune response from natural infection has a range, while the vaccine produces a measurable and predictable immune response. This is another reason why people with natural immunity should still be immunized.
Here is an explanation of why both shots of the Moderna or Pfizer vaccines are important.
People with COVID-19 antibodies may have a low risk of being reinfected, suggests a new study from the National Cancer Institute.
One-shot vaccine for survivors?
A new study suggests that those who have had COVID-19 may need only one shot of the vaccine for protection from future infections. The Pfizer and Moderna vaccines require two shots, given a few weeks apart.
The study, published in January, found that coronavirus survivors had far higher antibody levels after receiving two doses of the vaccine when compared to those who did not contract COVID-19. The study also found that people who previously had coronavirus were more likely to have side effects, including headaches, muscle aches and chills, after receiving their first vaccine shot.
A new study suggests that one shot of the Pfizer vaccine provides significant protection after one dose.
Q: How soon after recovery can people who had COVID-19 receive the vaccine? Should they wait for 90 days?
A: The CDC recommends waiting 90 days to get the COVID-19 vaccine if a person recovered from a COVID-19 infection and was treated with monoclonal antibodies or convalescent plasma.
Interactions between those treatment methods and the COVID-19 vaccines have not yet been studied, the CDC said.
People who tested positive for the illness, having only mild symptoms and not treated for the coronavirus, should wait until their doctor-recommended isolation period is over before getting the vaccine.
Q: If you have had the first vaccine dose without any allergic reaction, can you have an allergic reaction with the second dose?
A: There is a difference between an allergic reaction, and side effects. A severe allergic reaction requires treatment with epinephrine or hospitalization, according to the CDC.
Some people have a non-severe, immediate allergic reactions, such as wheezing, hives and swelling within four hours of being vaccinated.
People who experience a severe or non-severe allergic reaction from the first vaccine dose should not get the second shot, according to the CDC.
A CDC study published in January showed that between Dec. 14 and Dec. 23, 2020, there were 21 cases of anaphylaxis after the administration of a reported 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine (11.1 cases per million doses). Of these cases, 71% of these occurred within 15 minutes of vaccination.
This article by the Cleveland Clinic goes into more detail about the vaccines and allergic reactions.
If you get a red, itchy, swollen, or painful rash on the arm where you got the shot, you have COVID arm. If the first shot gives you a rash, you should still get the second shot at the recommended time, the CDC recommends. Try getting the second shot in the opposite arm.
Here is a story discussing why COVID arm isnt dangerous and why people who get it should receive their second dose of the vaccine.
Side effects vs. allergic reactions
Side effects from the vaccines injection site pain, fatigue, muscle pain, joint pain, headache, and redness at the injection site are expected for people who have had and have not had COVID-19.
The Clinics website addresses vaccine side effects, and if side effects are worse if a person has recovered from COVID-19.
Q: Does the lack of significant reaction from the second dose of vaccine indicate the vaccine is less effective?
A: Many people feel mild side effects, such as soreness at the injection site and low fever, after receiving the vaccine. But the lack of side effects is not an indication that the vaccine isnt working for you
Q: Should I take a PCR or antigen test to determine if the vaccine was effective?
A: The CDC doesnt promote antibody testing in order to find out who has immunity after getting the COVID-19 vaccine. Commercial antibody tests may not search for the same antibodies that the vaccine produces. Someone who has been immunized and is immune to the virus may still test negative for certain antibodies, health experts said.
In clinical trials, the Pfizer-BioNTech and Moderna vaccines protected against the coronavirus 95% of the time and 94% of the time, respectively. But that does not mean everyone who gets the vaccine would test positive for antibodies, health experts said.
Here is another story discussing why you shouldnt get a COVID-19 antibody test after vaccination.
Your coronavirus vaccine questions answered:
How will local drug stores keep the coronavirus vaccine on site if it needs to be cold? How will they avoid waste?
If Pfizer and Moderna vaccines are for people 16 and older, what does that mean for children? What about minors with pre-existing conditions?
Should cancer patients get the coronavirus vaccine?
Can you request one coronavirus vaccine if you have concerns about the other?
Should you get the coronavirus vaccine if youve had a bad reaction to the flu shot?
Are you contagious if you have side effects from the COVID-19 vaccine?
Can you mix and match two doses of coronavirus vaccine from different manufacturers?
Can I still get my second dose of coronavirus vaccine if I develop COVID-19 symptoms after the first?
Should you get the second vaccine if you contract COVID-19 after your first coronavirus vaccine dose?
Will your COVID-19 vaccine be less effective if you need to wait longer for the second dose?
If the coronavirus vaccine is 95% effective, how will you know if youre in the other 5%?
Why do I need to keep a mask on if Ive been vaccinated for coronavirus?
NEW DELHIIndias Bharat Biotech said its Covid-19 vaccine has proved 81% effective at protecting people in a large clinical trial, a report that could invigorate Indias inoculation drive and vaccine-diplomacy efforts.
Bharat Biotech is one of the worlds largest producers of vaccines but is little known outside of the industry. It has been developing a Covid-19 vaccine since the first half of 2020, which New Delhi approved for emergency use this year. India has already administered the vaccine to more than one million people.
Many Indians, however, have said they were reluctant to get the Bharat Biotech shot as they wanted to wait for the results of late-stage trials. Indias vaccination drive has been going much slower than anticipated and some healthcare workers said one of the reasons was that people didnt feel confident about the Bharat Biotech vaccine.
The company said it wanted to clear up any concerns with its announcement on Wednesday. The interim results of its Phase 3 trialwhich gave 25,800 people between the ages of 18 and 98 its vaccine or placebossuggest that it is effective against Covid-19. The company added that it has early indications that it is also effective against the more-contagious U.K. variant of the coronavirus.
Today is an important day for us, the company and also for the country and Indian science, said Krishna Ella, the chairman and managing director at Bharat Biotech.
PUNE, India, March 2, 2021 /PRNewswire/ -- The Global Demand for global corona virus vaccine market in terms of revenue was worth of USD 0.37 Billion in 2020 and is expected to reach USD 75.75 Billion in 2021. The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.
The study provides a crucial view of global corona virus vaccine market by segmenting the market based on infection type, vaccine type and region & country level. Based on infection, the corona virus vaccine market is segmented into HCoV-229E, HCoV-OC43, HKU1-CoV, NL63, MERS-CoV, New Haven CoV, SARS-CoV and SARS-CoV-2. Based on vaccine type, the market is segmented into S-protein based coronavirus vaccine, live attenuated coronavirus vaccine, inactivated coronavirus vaccine, MRNA vaccine and DNA-based vaccine. The regions covered in global virus testing diagnostic kits market are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, global virus testing diagnostic kits market is sub divided into U.S., Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Brazil, Mexico, GCC, Africa, etc.
Get Sample Copy of This Premium [emailprotected]https://brandessenceresearch.com/requestSample/PostId/1050
Key Companies Covered in the Corona Virus Vaccine market: Inovio Pharmaceuticals, Inc. Moderna, Inc., Protein Potential, LLC, Novavax, Inc., Synairgen PLC, AlphaVax, Inc., NanoViricides, Inc., Zydus Cadila, Bravovax, GeoVax, Altimmune, Janssen Pharmaceutical Companies, CanSino Biologics, Vaxart, Vaxil Bio Ltd
When most people in a community are vaccinated against a disease, the ability of the pathogen to spread is limited as vaccines can prevent infectious diseases. It greatly reduces the risk of infection by training the immune system to recognize and fight pathogens such as viruses or bacteria. As Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus i.e. SARS-CoV-2, which has spread rapidly throughout the world and in March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic. This pandemic has severely weakened health systems & economic and social progress globally. While countries, have taken strong measures to cover the spread of COVID-19 through better diagnostics and treatment, the coronavirus vaccines will provide a lasting solution by enhancing immunity and containing the disease spread. In response to the pandemic, the vaccine development process has been fast-tracked, as these vaccines safely deliver an immunogen which is a specific type of antigen that produces a resistant response for training the immune system to recognize the pathogen when it is come across naturally. There are many different COVID-19 vaccines are at development stage because it is not yet known which ones will be effective and safe. In April 2020; the access to COVID-19 Tools (ACT) Accelerator was launched to speed up development & delivery to countries of diagnostics, treatments and vaccines.
Factors such as the present coronavirus outbreak, increasing healthcare expenditures, growing concerns regarding Corona virus outbreaks at regular intervals and the growing need to protect populations across the globe from known as well as unencountered virus strains are expected to drive the growth of the market. For example; the 2019 novel coronavirus (2019-nCoV) was officially named as COVID-19 pandemic by the World Health Organization and has spread to more than 180 countries and the pandemic has had a negative impact on mental health. And, as of February 16th, 2021, India has about 10925710 confirmed cases of COVID-19 and globally, there are about 10,91,51,283 confirmed COVID-19 cases across 192 counties which has led to about 24,07,688 deaths.
In addition, health financing is necessary to the ability of health systems to maintain & improve human welfare and as there is a rapid growth in cases of COVID-19, which has challenged national healthcare capacity, testing systems at an advanced ICU and public health infrastructure level to develop the preventive measure for the pandemic. Thus, many regional governments are taking so many efforts and spending much more expenditures to develop a vaccine. For instance; on February 11th, U.S. President Joe Biden announced his administration has secured about 200 million more doses of the Moderna and Pfizer-BioNTech vaccines i.e. about 50% increase and also the Biden administration plans to deliver more doses directly to drugstores & pharmacies to speed up delivery of vaccine as part of about $1.9 trillion COVID-19 rescue plan. Hence, increasing healthcare expenditure for corona vaccine is also driving the growth of global coronavirus vaccine market. Moreover, increasing research & development for the corona vaccine may boost the growth of global coronavirus vaccine market growth within the forecast period. However, time required for each stage of clinical trials of vaccine and high costs associated with research & development of vaccines and drugs may hamper the market growth.
Get Methodology of this report @ https://brandessenceresearch.com/requestMethodology/PostId/1050
Global Coronavirus Vaccine Market: Market Player Analysis
Inovio Pharmaceuticals, Inc. Moderna, Inc., Protein Potential, LLC, Novavax, Inc., Synairgen PLC, AlphaVax, Inc., NanoViricides, Inc., Zydus Cadila, Bravovax, GeoVax, Altimmune, Janssen Pharmaceutical Companies, CanSino Biologics, Vaxart, Vaxil Bio Ltd
Geographically, North America region is expected to dominate the coronavirus vaccine market. This is due to increasing research & development activities for corona virus vaccine in the region and presence of major players such as Inovio Pharmaceuticals, Inc., Moderna, Inc. and Novavax, Inc. & among others, in this region. For instance, according to springer nature limited; Most COVID-19 vaccine development activity is in North America, with about 36 i.e. 46% of developers of the confirmed active vaccine candidates compared with about 14 (18%) in China, about 14 (18%) in Asia (excluding China) and Australia and about 14 (18%) in Europe. Also, on April 08, 2020, Novavax, Inc. Company has announced that it has identified a coronavirus vaccine candidate, NVX-CoV2373 and it will initiate a first-in-human trial in Mid-May of 2020.
Moreover, Europe is at second position in dominance and this is due to huge demand for coronavirus vaccine due to diverse coronavirus outbreaks in the current past, the presence of major players in countries in the region and rising investments in R&D activities, along with strong support from the government. For instance; on February 17th, 2021- Pfizer Inc. and BioNTech SE announced an agreement with the European Commission (EC) to supply an additional about 200 million doses of COMIRNATY-the companies' COVID-19 Vaccine to the 27 European Union (EU) member states. This new agreement is in addition to about 300 million doses which have already been committed to the EU through 2021 under the first supply agreement signed last year. The additional 200 million doses are expected to be delivered in 2021, with an estimated about 75 million to be supplied in the second quarter. So, the total number of doses to be delivered to the EU member states by the end of 2021 is about 500 million, with the potential to increase to about 600 million based on the option granted in the new agreement.
Global Market Trends of Corona Virus Vaccine.
In recent years, scientists and leading organizations are developing more than 110 vaccines by using wide range of techniques some of which are never been approved for medical purpose before and some of which are already well established. There are two sectors among the newest approaches for corona virus vaccine development that are viral vectors and RNA vaccines. These approaches are implementing for COVID-19 widely for numerous reasons such as their speed of development, scale and manufacturing fit as well as small dose size, all of which are highly desirable features for a rapid pandemic response. Both RNA and viral vectored vaccines have advents from doing investments in cell and gene therapies over the last 10 to 20 years. Some of the major trends in the global coronavirus vaccine market are.
A) Inactivated and Live Attenuated Vaccines:
Nowadays, almost all vaccines in use integrate an activated or weakened form of virus that is not able to cause diseases. When immune cells find out that they can make antibodies and these types of vaccines mainly contain selected viral proteins or inactivated viruses. These are pathogens that can be killed. The dead viruses can no longer multiply, but the body still determines them as intruders therefore, the body's defense system capable that antibodies are produced. The vaccinated individual does not develop the disease. This method utilizes based on tried and tested technology and it is already used in vaccines against diseases such as influenza, polio, whooping cough, hepatitis B, and tetanus.
Inactivated vaccines use a pathogen that can be modified so that it cannot replicate to stimulate individual immune system. They are safe because they cannot cause any type of diseases, but at the same time booster doses are particularly required. The inactivation approach includes heat, radiation or chemicals to eliminate the pathogen's genetic material, which stops it from replicating. Inactivated vaccines can trigger a strong immune reaction, but it is not as advantageous as reaction that live attenuated vaccines can produce. Owing to this reason, a person may need booster shots to ensure ongoing protection. The COVID-19 vaccines that Bharat Biotech, Sinovac and Sinopharm, have developed are inactivated vaccines. For example; Scientists at the private company Sinovac developed an activated COVID-19 vaccine called as CoronaVac, on the other hand, Bharat Biotech and the Indian Council of Medical Research co developed Covaxin.
Complete Access of This Report @https://brandessenceresearch.com/Checkout?report_id=1050
B) Genetic vaccines:
The gene-based vaccines include pure genetic information in the form of coronavirus DNA or mRNA type. Individual parts of genetic information from the pathogen are packed into nanoparticles and introduced into another cells. Once the vaccine is given inside the body, it should form harmless viral proteins that deliver strong immune protection.
o DNA Based Vaccine:
Many experimental vaccines do not give whole viruses. Instead, they offer genetic instructions for creating a viral protein. The protein can stimulate the immune system to produce antibodies and help in defensing against other coronaviruses. This method is known as a DNA vaccine. For example; the biotechnology company Inovio pharmaceuticals has previously developed experimental vaccines against MERS-CoV (INO-4700) and is evaluating a DNA vaccine against COVID-19. From the new study, comparing the immunogenicity of two investigational DNA based COVID 19 vaccines, researchers or scientists has shown the results that both prototypes induced potent immune response in mice. According to the scientists, their vaccines are based on a DNA-launched self-amplifying RNA (DREP) platform which is inexpensive, stable and also easy to produce and have a good safety profile.
o RNA Based Vaccine:
From the last few years, new technological innovation and research investment have enabled mRNA to become the milestone as a therapeutic tool in the fields of corona virus vaccine development. For example; the mRNA-1273 was the first mRNA vaccine which is developed by Moderna to be designed to fight against COVID-19 and has gained a time record of 63days from vaccine design to human trials. RNA vaccines hold more benefits including faster, cheaper, more adaptable and easier to volume produce than other vaccines. For example; BioNTech and Pfizer Company launched a coordinated program to compare RNA based COVID-19 vaccine candidates in clinical studies conducted in Germany and the United States. The program was arranged to support the selection of a single vaccine candidate and dose level for a pivotal international safety and efficacy trial purpose.
C) Viral Vector Vaccine:
Viral vectors use modified viruses as boosters to access genetic and cellular material are one of the most commonly deployed tools in the search for a vaccine for SARS-CoV-2. Furthermore, scientists are increasingly using viral vector vaccines in therapeutics research well before the coronavirus pandemic, due to their use in gene therapy and cell therapy has proven to be effective. Now, those same applications are being repurposed to develop a coronavirus vaccine. These vaccines use a well-established inactivated or killed viral vector including adenovirus to evaluate proteins of SARS COV2, so that proteins can be determined by individual immune system to produce an immune response.
Synthetic biology is a field of science which consists of redesigning of organisms for useful purposes with the help of engineering technique for making new abilities. synthetic biology market in terms of revenue was estimated to be USD 7.54 Billion in 2019 and is expected to reach USD 34.51 Billion in 2026, growing at a CAGR of 21.9% from 2020 to 2026.
Continued Corona Virus Vaccine Research Report
Have a Look at Related Report?
Vaccine Contract Manufacturing Marketis valued at USD 992.84 Million in 2018 and expected to reach USD 1559.52 Million by 2025 with the CAGR of 10.2% over the forecast period.
Vaccine Delivery Devices Marketis valued at USD 3927.1 Million in 2018 and expected to reach USD 6557.7 Million by 2025 with the CAGR of 7.60% over the forecast period.
Immunotherapy Drug Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2025. Increasing geriatric population and adoption of targeted therapies with lesser side effects are major key factor which drives the Immunotherapy Drug Market.
Vaccines Market: Rising burden of several infectious and non-infectious diseases, increasing government and non government support for vaccine development, and increasing Research and Underdevelopment likely to augment the growth of Global Vaccine Market.
Veterinary/Animal Vaccines Market2020 By Type (Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vaccines And DNA Vaccines), By Diseases (Porcine Vaccine, Poultry Vaccine, Livestock Vaccine, Companion Animal Vaccine, Aquaculture Vaccine, Others Vaccine), By Animal Type (Companion , Livestock), By Route Of Administration (Oral, Parenteral , Others), By Distribution Channel (Animal Hospitals, Animal Clinics, Pharmacies & Drug Stores , Others) Forcast To 2025
Global HIV Vaccines Market: Global Market Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027
Top 5 Bioinformatics Companiesin the Global Market 2021
About Brandessence
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Website:https://brandessenceresearch.comArticle:https://industrywatchnews.com/
ContactMr. Aniket Patil[emailprotected]Email : [emailprotected]Corporate Sales: +44-2038074155Asia Office: +917447409162
SOURCE Brandessence Market Research And Consulting Private Limited
As of 28 February 2021, the Indonesian Government has announced 1,334,634 confirmed cases of COVID-19 in all 34 provinces in Indonesia, with 155,765 active cases, 36,166 deaths, and 1,142,703 people that have recovered from the illness. The government has also reported 71,668 suspected cases.
Recently, the bed occupancy rate (the number of filled beds and patients in Covid-19 referral hospitals) has decreased at the national level. There is no hospital occupancy rate that is above 70 percent, with the highest rate in Banten Province at 65 percent. as of 22 February 2021. Similarly, the occupancy rate of ICUs in COVID-19 referral hospitals in seven provinces of Java and Bali Islands has also decreased, with an average below 70 percent. This data shows an improvement in the situation, compared to that of January 2021.
Following a 6.2 magnitude earthquake that occurred in West Sulawesi Province on 15 January 2021, the provincial COVID-19 Task Force reported significant increases of the number of COVID-19 infections in the province; on 6 January 2,020 COVID-19 confirmed cases were detected, and the number skyrocketed to 5,042 confirmed infected people on 19 February. Earthquake survivors, community and humanitarian responders have been requested to strictly apply the health protocols of wearing masks, washing hands frequently and maintaining social distance.
On 18 February, the Head of the COVID-19 Response and National Economic Recovery team (PCPEN) announced that Indonesia has secured more than 420 million doses of the vaccine for 180 million people; for 2021 the total amounts to 340.5 million vaccines (consisting of 125.5 million of the Sinovac vaccine, 52 million of Novavax, 54 million Covax / Gavi, 59 million of AstraZeneca, and 50 million doses of Pfizer); in 2022 totals will amount to 86.3 million vaccines (Novavax 22 million, Covax / Gavi 24 million, AstraZeneca 23.8 million, and Pfizer 16.5 million doses).
Vaccinations for medical workers are ongoing, and the implementation of the second phase of vaccination targeting 21.5 million elderly people and workforce in selected sectors started in mid-February 2020. As of 26 February, about 2.6 million doses of the coronavirus vaccine have been administered in Indonesia. As many as 1.6 million citizens have received the vaccine, with around one million of them having received the second shot of the vaccine that is coproduced by the state-owned pharmaceutical company Bio Farma and Sinovac Biotech.
The private vaccination scheme (Gotong Royong or Mandiri) will run alongside with the national programme, following the Regulation by the Minister of Health, Number 10 of 2021 concerning the Implementation of Vaccinations in the Context of the COVID-19 Pandemic, stipulated on 24 February 2021. The private scheme will target employees, family members and other related individuals. Currently, more than 8,000 companies have signed up for the private scheme, with procurement to be done through PT Bio Farma and PT Kimia Farma.
After evaluating the Restrictions on the Conduct of Public Activities (PPKM) in Java and Bali, which began on 11 January 2021, the Government implemented a micro-scale PPKM that started on 9 February 2021 and is based on the Minister of Home Affairs Instruction Number 3 of 2021. In micro-scale PPKM, there are provisions for the establishment of a Command Post for the COVID-19 response at the village level, which is tasked to manage the following zoning at the neighborhood (RT - Rukun Tetangga) level:
Green zone: no cases of corona virus transmission in one RT area.
Yellow zone: there are 1-5 houses that have confirmed positive for Covid-19 in one RT during the last seven days.
Orange zone: there are 6-10 houses with positive confirmed cases in one RT during the last seven days.
Red zone: there are more than ten houses with positive confirmed cases in one RT during the last seven days.In this red zone, a ban on crowds of more than three people and out-and-out activities starting at 8:00 p.m. and the closure of public facilities such as places of worship, children's playgrounds and other public facilities are implemented.
The Micro-scale PPKM also adjusts operating hours of restaurants and shopping centers to 21:00 hours, and a maximum of 50 percent work from office. The micro-scale PPKM will last until 8 March 2021, with a possible extension.
Programs on the COVID-19 response and national economic recovery in 2021 continue, with an adjusted Government budget of IDR. 699.4 trillion. The budget includes four aspects:
Health: IDR. 176.3 trillion,
Social protection: IDR. 157.4 trillion,
Financial support to micro, small and medium enterprises (MSMEs) and cooperatives: IDR. 186.8 trillion,
Business and taxes: IDR. 53.9 trillion, and
Priority Program: IDR. 125.1 trillion.
